Menu Search
Equities

Aurinia Pharmaceuticals Inc

IKAP:FRA

Aurinia Pharmaceuticals Inc

Actions
  • Price (EUR)6.23
  • Today's Change0.000 / 0.00%
  • Shares traded200.00
  • 1 Year change-19.22%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 08:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

  • Revenue in USD (TTM)207.11m
  • Net income in USD-50.35m
  • Incorporated2009
  • Employees300.00
  • Location
    Aurinia Pharmaceuticals Inc#140, 14315 - 118 AVENUEVICTORIA T5L 4S6CanadaCAN
  • Phone+1 (250) 744-2487
  • Fax+1 (604) 369-4115
  • Websitehttps://www.auriniapharma.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.